| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8725749 | Gastroenterología y Hepatología | 2017 | 10 Pages |
Abstract
Switching to biosimilar infliximab in a real-life cohort of IBD patients in clinical remission did not have a significant impact on short-term clinical outcomes. The factors associated with relapse were similar to those expected in patients continuing with Remicade®.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Lourdes Guerrero Puente, Eva Iglesias Flores, José Manuel BenÃtez, Rosario Medina Medina, Isabel Salgueiro RodrÃguez, Patricia Aguilar Melero, Manuel Jesús Cárdenas Aranzana, Rafael González Fernández, Bárbara Manzanares Martin,